In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder

Abstract excerpt

Introduction: Glucagon-Like Peptide-1 Receptor (GLP1R) agonists have become widespread anti-obesity/diabetes pharmaceuticals in the United States. Aim: This article aimed to provide our current knowledge on the plausible mechanisms linked to the role of Ozempic (Semaglutide), which is generalized as one of the anti-addiction compounds. Methods: The effects of GLP1R agonists in Alcohol Use Disorder (AUD) and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Diabetes Treatment and Management
• Share to Neuropeptides and Animal Physiology
• Share to Regulation of Appetite and Obesity